IRCT20210901052358N3尚未招募未知
Comparisson of the effectiveness of Tocilizumab and Tofacitinib on the outcomes of patients with severe COVID-19
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 no limit（—）
- 性别
- All
入选标准
- •Laboratory confirmation of COVID-19 virus by PCR
- •Severe cases according to the World Health Organization guideline (peripheral blood oxygen saturation less than 90%, respiratory rate more than 30 per minute or symptoms of severe respiratory distress such as use of auxillary respiratory muscles or inability to complete sentences)
- •Body mass index less than 40 kg per square meter
- •No immunosuppressive diseases (primary, secondary and organ transplant defects, chemotherapy or radiotherapy)
- •Patient willingness to participate in the study
- •Non-pregnant and non-lactating women
- •Serum CRP level greater than 75 mg / L
- •Do not receive immunomodulatory drugs for 6 months before
- •No history of severe hypersensitivity to tosilizumab and tofacitinib and similar compounds
- •No history of active gastric ulcer, active diverticulitis and other gastrointestinal diseases with risk of intestinal perforation
- •No active hepatitis or tuberculosis or a bacterial or fungal or viral infection other than COVID-19
- •No history of chronic kidney disease (GFR less than 30 ml / min)
排除标准
- •Severe drug allergy and anaphylactic shock
- •Death in the first 24 hours of hospitalization
- •Increase in liver enzymes to more than 10 times the normal upper limit
- •Decrease in neutrophil count to less than 500 cells per microliter
- •Decrease in platelet count to less than 50,000 cells per microliter
- •GFR less than 30 ml per minute
研究者
相似试验
已完成
不适用
Efficacy and Safety of treatment with tocilizumab in refractory patients with Takayasu ArteritisTakayasu arteritisJPRN-UMIN000007845Department of Cardiovascular Medicine Graduate School of Medicine Osaka University15
招募中
2 期
Evaluation the Efficacy and Safety of Tocilizumab in COVID-19COVID-19 pneumonia.Confirmed diagnosis of COVID-19RA01.0IRCT20151227025726N13Shahid Beheshti University of Medical Sciences40
尚未招募
不适用
Comparison of Tocilizumab Vs Itolizumab in covid 19 patient.CTRI/2020/10/028325AIIMS Patna
招募中
3 期
The effect of tocilizumab, plasmapheresis and tocilizumab plasmapheresis combination in COVID 19 patientsCOVID-19.COVID-19 diseaseU07.1IRCT20220123053807N1Yazd University of Medical Sciences90
招募中
2 期
Evaluation of the Effects of Tocilizumab Administration in Hospitalized COVID-19 PatientsIRCT20151227025726N29Iran University of Medical Sciences50